Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years. Prior to his role here, Dr. Noh was the Director of the Biotechnology Lab at Kolon Central Research Park. Dr. Noh holds a Ph.D. and M.S. from the Korea Advanced Institute of Science and Technology in Molecular Biology.

Dr. Seng-Ho Jeon holds a Ph.D. in Pharmaceutical Sciences from Yonsei University, an MBA from Aalto University School of Business, a Master’s degree in Pharmaceutical Sciences from Seoul National University, and a Bachelor’s degree in Pharmacy from Seoul National University.

He served as CEO and President of Daewoong Pharmaceutical from 2018 to 2024, where he led the company’s growth and global expansion. He also held concurrent leadership roles, including CEO of Affycell Therapeutics (2020 to April 2024) and CEO of Daewoong Investment (2023 to April 2024). In addition, he has been serving as a board member of Korea Science & Technology Holdings since 2023, and as an advisor and board member at the Future Medicine Research Foundation since 2021.

In addition to his roles as the Inside Director at Kolon TissueGene, Kyu Ho Lee previously served as Chief Strategy Officer of key Kolon group affiliates and as CEO of Kolon Mobility Group Corporation. He currently holds the positions of Vice Chairman of Kolon Group and CEO of Kolon Corporation. He earned a Bachelor of Science in Hotel Administration from Cornell University.

Jung In Kim joined Kolon TissueGene, Inc. in December, 2021 as the Chief Financial Officer. Before she joined Kolon TissueGene, she served as a director of the Management and Finance division in Kolon Corporation. She received his Bachelor of Arts in Mathematics at Kookmin University in Korea and acquired her CPA license from Korea Institute of Certified Public Accountant.

Jan Van Acker served as Senior Vice President, Global Human Health at Merck & Co., Inc. (MSD Switzerland). He currently serves as a Strategic Advisor at the ARC Innovation Hub of Sheba Medical Center and as a Strategic Advisor in healthcare and biopharmaceuticals. He holds a Master of Science in Mechanical Engineering from Universiteit Gent and Master’s degrees in Management and in Technology and Policy from MIT.

Dr. Robert Ang was previously the President & Chief Executive Officer of Vor Biopharma, a NASDAQ-listed biotechnology company developing cell therapies for cancer patients. Dr. Ang also has extensive experience in biotech business development executive alongside venture capital and strategy consulting. Dr. Ang received his MBBS medical degree from the University of Western Australia, received his MBA from Columbia University, and is a board member at the Alliance for Regenerative Medicine.

Young J. Kim’s founded and successfully led companies in the U.S. commercial and government service industries for many years. He received his Doctorate in Engineering Management at George Washington University.